AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

AstraZeneca PLC

Angelini Pharma is an international pharmaceutical company focused on the research, development, and commercialization of health solutions with a preeminent focus on brain health, including mental health and epilepsy, and consumer healthcare.

Angelini Pharma

Cordia Pharma LTD UK operates in the healthcare industry, providing business process optimization, technology solutions, strategic sourcing, and digital transformation services. This description is self-described.

Cordia Pharma LTD UK

CVS is an online drugstore and pharmacy that provides prescription services, health information, and wellness products. Self-described as a provider of health and wellness solutions.

We're transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet. For more information, visit www.astrazeneca.com.

Community Guidelines: bit.ly/2MgAcio

ADC Therapeutics

Viela Bio

Cellular Biomedicine Group

Moderna

FibroGen

Innate Pharma

Nektar Therapeutics

PhaseBio Pharmaceuticals

Rani Therapeutics

AstraZeneca

Join us live at the London Stock Exchange’s Market Open Ceremony with our CEO Pascal Soriot and our leadership team as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science.

We are pleased to report 2023 was another year of double-digit growth and scientific progress, with investments in exciting areas of science that lay the foundations for continued long-term success. 

This year we are excited to celebrate our 25th anniversary with our teams around the world. Thank you for unlocking the power of what science can do for people, society and the planet. 

#AZN #WhatScienceCanDo

Our Full Year and Q4 2023 Results announcement will be available from 07:00 GMT on Thursday 8 February 2024. 
 
Join the accompanying webcast for investors and analysts at 11:45 GMT – you can register to attend here: https://lnkd.in/eBerW6Vc

Join us live tomorrow at the London Stock Exchange’s Market Open Ceremony as we announce our FY and Q4 2023 Results and mark 25 years of pioneering science. 

Set up a reminder to watch here: https://learn.az/6042V3qhg

Innovations in cell therapy are advancing the treatment of some blood cancers for patients. However, there are challenges in using the therapy to treat other types of cancer.  

Susan Galbraith, EVP of Oncology R&D, shares her thoughts on how we can expand the potential of cell therapies to reach more people impacted by cancer. https://learn.az/6049psAnh 

World Economic Forum 
#WorldCancerDay #CloseTheCareGap

Congratulations to Prof Sir Mene Pangalos, who has received the prestigious BioIndustry Association (BIA) Lifetime Achievement Award. The award celebrates not only Mene’s career, but recognises the incredible impact scientists have on patients and society. Learn more: https://learn.az/6047T0fpJ 

#WhatScienceCanDo

Providing young people access to quality science, technology, engineering and mathematics (#STEM) education can inspire them to pursue their interests and explore potential careers in STEM.

Our global programmes, supported by our four key pillars, foster inclusive environments dedicated to inspiring the next generation of scientists, researchers and innovators. 

Learn more: https://learn.az/6049T5GW1

We’re taking action to protect and restore ecosystems by lowering the environmental footprint of healthcare whilst investing in nature and biodiversity. 

As part of our commitment to following the science and to transparently communicating our progress on how we are protecting biodiversity, this week, we became an Early Adopter of the Taskforce on Nature-related Financial Disclosures (TNFD). 

TNFD will support us in identifying and assessing our nature-related dependencies, impacts, risks, and opportunities.

Discover more here: https://learn.az/6047rtPlt

#TNFDEarlyAdopter #TNFD #WEF24

Health must be front and centre of tackling the climate crisis. By taking a health-centred approach, we can improve both the sustainability and resilience of our health systems. 

We co-hosted a discussion on this critical topic with Vanessa Kerry, MD MSc from the World Health Organization and Seed Global Health, and Devex on the practical steps needed to strengthen financing of health systems in the face of climate change.

Expanding the resources necessary to drive transformative action is urgent for the health of people, society and our planet. #ItStartsWithHealth #WEF24

We’re proud to have launched a renewable power agreement in China together with Lonza, Novartis, Novo Nordisk, Roche and Envision Energy. 

Convened through the The Sustainable Markets Initiative Health Systems Task Force, this milestone agreement is the first time the pharmaceuticals sector has collaborated on green power in China, and it’s set to achieve annual CO2e savings of around 120,000 tonnes. That’s the equivalent of taking 25,000 cars off the road.
 
We can achieve more when we work in partnership. 
 
Learn more: https://lnkd.in/eTVhjeqe

Metric
Company Name	AstraZeneca PLC	Angelini Pharma	Cordia Pharma LTD UK	CVS
Symbol	AZN
MSH ID	COM:ASTRAZENECA	COM:ANGELINIPHARMA	COM:CORDIAPHARMA	COM:CVS
Market	STOCKS	PRIVATE	PRIVATE	PRIVATE
Sector	Healthcare	Healthcare & Health Services	Commercial & Professional Services	Healthcare & Health Services
Industry	Drug Manufacturers - General	Pharmaceuticals	Healthcare & Health Services	Pharmacy and Retail Health
Country	GB	IT	GB	US
Stage
Employee Count	89.90K
Website	astrazeneca.com	angelinipharma.com	cordiapharma.com	cvs.com
LinkedIn	astrazeneca		cordia-pharma-ltd
Founders

Metric
Market Cap	2.39B
Enterprise Value
Monthly Web Traffic	758.60K	15.77K
Web Traffic Growth	-0.13	-0.39
Valuation
Raised Capital

Metric
Revenue	45.81B
Revenue (LTM)
Revenue (NTM)
Gross Profit	37.54B
EBITDA	13.91B
Operating Income	8.19B
Net Income	5.96B
EPS	3.84
Diluted EPS	3.81
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.82
Operating Profit Margin	0.19
EBITDA Margin	0.30
Net Profit Margin	0.13
Return on Equity	0.17
Return on Assets	0.06
Return on Capital Employed	0.12

COM:ASTRAZENECA

AstraZeneca plc

Last Close

10,474.00

25/11 09:24

Market Cap

1.88B

Beta: -

Volume Today

156.03K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	34.12
P/B Ratio	5.41
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	5.51
EV Multiple	16.93

Metric
Days Sales Outstanding
Days Payables Outstanding	846.26
Days Inventory Outstanding	239.45
Operating Cycle	317.44
Cash Conversion Cycle	95.22
Asset Turnover	0.47

Metric
Operating Cash Flow	10.35B
Free Cash Flow	6.57B
Cash Flow to Debt	0.36
Operating Cash Flow/Sales	0.23
Free Cash Flow Yield	0.03

Metric
Cash & Equivalents	5.84B
Accounts Receivable
Inventory	5.42B
Goodwill	20.05B
Debt to Capitalization	0.48
Debt to Assets	0.30
Current Ratio	0.79
Quick Ratio	0.70

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue	0.23
SG&A to Revenue